Xenophon Xenophontos, MD
Vascular Surgery · Garden City, NYNPI 1790735991
Payments from drug & device makers
What this record shows
This record is dominated by other: $64,400 of the $64,677 with a category attached, or 99.6%. Convatec Inc. accounts for 99.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $64,531 and has fallen 99.9% since, to $56 in 2025.
Across 11 payments — averaging $5879.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$64K
- Penumbra, Inc.$131
- Triad Life Sciences Inc.$73
- Boston Scientific$37
- Mimedx Group, Inc.$19
- Next Science LLC$17
What the payments were for
- Food & beverage$2770%
- Other$64,400100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 5 | $64,400 |
| Penumbra, Inc. | 1 | $131 |
| Triad Life Sciences Inc. | 2 | $73 |
| Boston Scientific | 1 | $37 |
| Mimedx Group, Inc. | 1 | $19 |
| Next Science LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$64,400
- Indigo System$131
How this compares
$64,677 in reported general payments places this provider in the 85th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 68 | $69,316 |
| EliquisApixaban | 21 | $18,913 |
| Cilostazol | 65 | $1,556 |
| ClopidogrelClopidogrel Bisulfate | 68 | $856 |
| Cephalexin | 19 | $364 |
| Clindamycin Hcl | 16 | $221 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $189 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $134 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Garden City
- Neal CayneGarden City$108K
- Gary GelbfishNew York$1.9M
- Sundaram RavikumarDobbs Ferry$1.8M
- Antonios GasparisHuntington$1.5M
- Sonya NoorBuffalo$991K
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
- Peter FariesNew York$494K
- Robert RheeBrooklyn$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.